IDL Diagnostics AB (publ) (FRA:80R)

Market Cap	8.25M -15.4%
Revenue (ttm)	5.32M +7.6%
Net Income	-398.54K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0232
Previous Close	0.0248
Day's Range	0.0232 - 0.0232
52-Week Range	0.0110 - 0.0356
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 25
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 80R

Financial Performance

In 2025, IDL Diagnostics AB's revenue was 53.11 million, a decrease of -7.54% compared to the previous year's 57.44 million. Losses were -12.15 million, 264.0% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error